In a research report issued today, Vertex Pharmaceuticals (VRTX) was downgraded by analyst Andrew Fein at H.C.
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on Vertex Pharmaceuticals (VRTX) and increased his price target to $107.00 (from $92.
In a research note released this morning, H.C.
In a research note released this morning, Janney Montgomery Scott reiterated coverage on Vertex Pharmaceuticals (VRTX) with an Outperform rating and $90 fair value estimate. A data …
